View Financial HealthArcher Materials 배당 및 자사주 매입배당 기준 점검 0/6Archer Materials 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Sep 19Archer Materials Limited, Annual General Meeting, Nov 20, 2025Archer Materials Limited, Annual General Meeting, Nov 20, 2025.공시 • May 05+ 1 more updateArcher Materials Limited Announces Resignation of Damien Connor, Chief Financial Officer, Effective 30 June 2025Archer Materials Limited announced Mr. Damien Connor, the Company's Chief Financial Officer has provided notice of resignation to the Company. Mr. Connor has agreed to assist as required to ensure a smooth transition through to 30 June 2025.공시 • Oct 18Archer Materials Limited, Annual General Meeting, Nov 20, 2024Archer Materials Limited, Annual General Meeting, Nov 20, 2024. Location: stone & chalk sydney scaleup hub, level 2, 477 pitt street, haymarket, 2000., Australia공시 • Jul 13Mohammad Choucair to Step Down as Chief Executive Officer of Archer Materials Limited in January 2025Archer Materials Limited announced the departure of Dr. Mohammad Choucair as Chief Executive Officer ("CEO"). Mohammad will step down from the CEO role in January 2025 to ensure a smooth transition and handover. Mohammad retires from the Company for personal reasons.공시 • Mar 15Archer Materials Limited Designs Miniaturised Version of Biochip Biochip Graphene Field Effect Transistor ChipArcher Materials Limited has designed a miniaturised version of its Biochip graphene field effect transistor (“gFET”) chip for fabrication at a commercial foundry. The Archer Biochip contains a sensing region of which the gFET is the core component. Each gFET chip contains multiple gFETs, each of which is a transistor, which acts as a sensor. Archer has miniaturised the total chip size by redesigning the layout of the circuits creating these gFET transistors. The new miniaturised design has been sent to a foundry partner for a whole-wafer fabrication of reduced size gFET chips, which Archer intends to integrate with other parts of the Biochip technology. The new gFET chip design has been significantly reduced in size over earlier designs of 10mm x 10mm to 1.5mm x 1.5mm. It will be tested on a four-inch wafer which is expected to produce 1375 chips on it, compared to the 45 chips produced using earlier designs in previous four-inch wafer fabrication runs. The chip will be fabricated by Applied Nanolayers (“ANL”), based in the Netherlands, which has fabricated earlier designs of Archer’s gFETs (ASX ann. 14 September 2023). Independent to wafer runs at ANL, Archer has also sent gFET designs to a foundry in Spain for fabrication, with delivery anticipated within the first half of 2024 (ASX ann. 11 December 2023). Archer applies the ‘fabless’ chipmaker model by designing, researching, and developing its chips, while outsourcing manufacturing to specialised companies in the semiconductor supply chain. This includes the creation of a new miniaturised Biochip gFET chip design, sending the design for a whole wafer run in a commercial foundry, and deciding on the chip assembly and semiconductor device electronics packaging and related electrical testing. The wafer will be diced and assembled at Archer’s newly established outsourced semiconductor assembly and testing (“OSAT”) partner, AOI Electronics in Japan. The OSAT includes moulding, dicing, and lead frame design for this dedicated wafer assembly, and also device electronic shorting and related packaging testing. These new capabilities are key in advancing the Biochip development to interfacing and integration with miniaturised gFET chip sensor designs. Delivery of the packaged chips is anticipated in mid-2024.공시 • Nov 02Archer Materials Limited Demonstrates Multiplexing Readout for its Advanced Biochip Graphene Field Effect Transistor DeviceArcher Materials Limited has demonstrated multiplexing readout for its advanced Biochip graphene field effect transistor (gFET) device. Archer confirmed single-device multiplexing using four advanced gFETs as sensors, which were integrated into the Archer advanced Biochip platform that was announced on 14 September 2023. This is significant as Archer intends to apply its multiplexing capability in the Biochip to test for multiple diseases on a single chip at once. Archer designed and developed the new hardware and software systems to readout the signal from the four advanced gFET sensors at once on a single chip. This is a significant advance over the earlier generation of the Biochip system, which could only activate one-sensor-at-a-time. The new Biochip system with multiplexing capability also provides automated hands-free operation, as it integrates liquid handling automation and data acquisition. The software developed by Archer can display all single and time series measurements in real-time for the four gFET sensors simultaneously.공시 • Oct 28Archer Materials Limited, Annual General Meeting, Nov 29, 2023Archer Materials Limited, Annual General Meeting, Nov 29, 2023, at 10:30 E. Australia Standard Time. Location: KPMG, Level 38, Tower Three, International Towers Sydney 300 Barangaroo Avenue Sydney New South Wales Australia Agenda: To consider he Remuneration Report for the year ended 30 June 2023; to consider Re-election of Bernadette Harkin as a Director; to consider Approval of Issues of Securities under the New Performance Rights Plan and Share Option Plan; to consider Modification of the Company's Constitution; to consider Approval of 10% additional placement capacity; to consider Renewal of proportional takeover provisions in the Constitution; and to consider other matters.공시 • Aug 01Archer Materials Limited Further Enhances Biochip gFET Design for Advanced Sensing and Send to Commercial Foundry PartnerArcher Materials Limited has developed a next generation biochip fabrication to better detect and control disease samples on a single graphene field effect transistor ("gFET") design. The gFET design also has functional surfaces and components, for both the sensor and control of the biochip platform. There is also an integration of gFET design components that allow for the real-time fine tuning and control of the electronic properties of the graphene. This has the potential advantage of biosensors that are re-usable, leading to an extended device lifetime. In addition, Archer has improved its biochip system platform testing capabilities to develop a more accurate sensor. The upgraded automated testing platform conducts both control software and readout hardware with improved efficiency. The software is also progressing towards automated data analysis, so end users can extract high quality data. This new more complex gFET design complements the proof-of-concept biosensing gFET announced on 13 July 2023. The earlier design was submitted to a commercial foundry for a Multi-Project Wafer run, with the completed devices expected to be delivered by the end of 2023. The new advanced device designs which are the subject of this announcement have now been submitted to a foundry in the Netherlands for a whole wafer run (the previous 'simpler' design was submitted to a foundry in Germany for a Multi- Project Wafer ("MPW") run). An MPW is where Archer's device design is imprinted on a small area of a wafer with the designs of other companies on the same wafer. The new more complex gFet design will be fabricated all over one, stand-alone four-inch wafer. The new advanced gFET device design and whole wafer run in a commercial foundry is an example of how Archer is now moving towards a streamlined commercialization model that closely aligns to the 'fabless' model (i.e. Archer focuses on designing and developing its chips and outsources the manufacturing to specialized foundries). The new gFET device designs and related processes form the basis of intellectual property that is 100% owned by Archer.공시 • Jul 14Archer Materials Limited Transfers Biochip Graphene Sensor Technology Design to A Commercial Fab to Verify ScalabilityArcher Materials Limited has completed a proof of concept biosensing graphene transistor for use in its biochip, and submitted the technology design to a commercial foundry to verify scalability. The Archer-designed gFET sensing chips will be produced by a commercial foundry, with the aim of Archer validating its design to ensure appropriate scalability for the manufacturing process. Archer expects completed runs to arrive at the end of 2023. The runs will be evaluated to test which foundry and process are best suited to Archer's technology. Archer's design and process can then be scaled to manufacture complete wafers containing the graphene-based sensors for biochip integration in collaboration with a range of different commercial foundries. Archer has, in parallel, started discussions with potential global foundry partners for initial small production runs of its graphene chip designs to evaluate the reliability of the product. The latest development follows the recent announcement on 10 March 2023 in which the Company gained electronic control of the sensitivity of its incorporated gFET devices so it can better target biomolecules. This followed Archer's early-stage biochip prototype with an integrated system platform for biosensing announced to the market on 16 November 2022, after having developed a 'wettable' gFET announced on 24 October 2022.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 ARRX.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: ARRX.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Archer Materials 배당 수익률 vs 시장ARRX.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (ARRX.F)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.3%업계 평균 (Semiconductor)0.3%분석가 예측 (ARRX.F) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ARRX.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ARRX.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ARRX.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: ARRX.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 21:24종가2026/05/22 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Archer Materials Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Sep 19Archer Materials Limited, Annual General Meeting, Nov 20, 2025Archer Materials Limited, Annual General Meeting, Nov 20, 2025.
공시 • May 05+ 1 more updateArcher Materials Limited Announces Resignation of Damien Connor, Chief Financial Officer, Effective 30 June 2025Archer Materials Limited announced Mr. Damien Connor, the Company's Chief Financial Officer has provided notice of resignation to the Company. Mr. Connor has agreed to assist as required to ensure a smooth transition through to 30 June 2025.
공시 • Oct 18Archer Materials Limited, Annual General Meeting, Nov 20, 2024Archer Materials Limited, Annual General Meeting, Nov 20, 2024. Location: stone & chalk sydney scaleup hub, level 2, 477 pitt street, haymarket, 2000., Australia
공시 • Jul 13Mohammad Choucair to Step Down as Chief Executive Officer of Archer Materials Limited in January 2025Archer Materials Limited announced the departure of Dr. Mohammad Choucair as Chief Executive Officer ("CEO"). Mohammad will step down from the CEO role in January 2025 to ensure a smooth transition and handover. Mohammad retires from the Company for personal reasons.
공시 • Mar 15Archer Materials Limited Designs Miniaturised Version of Biochip Biochip Graphene Field Effect Transistor ChipArcher Materials Limited has designed a miniaturised version of its Biochip graphene field effect transistor (“gFET”) chip for fabrication at a commercial foundry. The Archer Biochip contains a sensing region of which the gFET is the core component. Each gFET chip contains multiple gFETs, each of which is a transistor, which acts as a sensor. Archer has miniaturised the total chip size by redesigning the layout of the circuits creating these gFET transistors. The new miniaturised design has been sent to a foundry partner for a whole-wafer fabrication of reduced size gFET chips, which Archer intends to integrate with other parts of the Biochip technology. The new gFET chip design has been significantly reduced in size over earlier designs of 10mm x 10mm to 1.5mm x 1.5mm. It will be tested on a four-inch wafer which is expected to produce 1375 chips on it, compared to the 45 chips produced using earlier designs in previous four-inch wafer fabrication runs. The chip will be fabricated by Applied Nanolayers (“ANL”), based in the Netherlands, which has fabricated earlier designs of Archer’s gFETs (ASX ann. 14 September 2023). Independent to wafer runs at ANL, Archer has also sent gFET designs to a foundry in Spain for fabrication, with delivery anticipated within the first half of 2024 (ASX ann. 11 December 2023). Archer applies the ‘fabless’ chipmaker model by designing, researching, and developing its chips, while outsourcing manufacturing to specialised companies in the semiconductor supply chain. This includes the creation of a new miniaturised Biochip gFET chip design, sending the design for a whole wafer run in a commercial foundry, and deciding on the chip assembly and semiconductor device electronics packaging and related electrical testing. The wafer will be diced and assembled at Archer’s newly established outsourced semiconductor assembly and testing (“OSAT”) partner, AOI Electronics in Japan. The OSAT includes moulding, dicing, and lead frame design for this dedicated wafer assembly, and also device electronic shorting and related packaging testing. These new capabilities are key in advancing the Biochip development to interfacing and integration with miniaturised gFET chip sensor designs. Delivery of the packaged chips is anticipated in mid-2024.
공시 • Nov 02Archer Materials Limited Demonstrates Multiplexing Readout for its Advanced Biochip Graphene Field Effect Transistor DeviceArcher Materials Limited has demonstrated multiplexing readout for its advanced Biochip graphene field effect transistor (gFET) device. Archer confirmed single-device multiplexing using four advanced gFETs as sensors, which were integrated into the Archer advanced Biochip platform that was announced on 14 September 2023. This is significant as Archer intends to apply its multiplexing capability in the Biochip to test for multiple diseases on a single chip at once. Archer designed and developed the new hardware and software systems to readout the signal from the four advanced gFET sensors at once on a single chip. This is a significant advance over the earlier generation of the Biochip system, which could only activate one-sensor-at-a-time. The new Biochip system with multiplexing capability also provides automated hands-free operation, as it integrates liquid handling automation and data acquisition. The software developed by Archer can display all single and time series measurements in real-time for the four gFET sensors simultaneously.
공시 • Oct 28Archer Materials Limited, Annual General Meeting, Nov 29, 2023Archer Materials Limited, Annual General Meeting, Nov 29, 2023, at 10:30 E. Australia Standard Time. Location: KPMG, Level 38, Tower Three, International Towers Sydney 300 Barangaroo Avenue Sydney New South Wales Australia Agenda: To consider he Remuneration Report for the year ended 30 June 2023; to consider Re-election of Bernadette Harkin as a Director; to consider Approval of Issues of Securities under the New Performance Rights Plan and Share Option Plan; to consider Modification of the Company's Constitution; to consider Approval of 10% additional placement capacity; to consider Renewal of proportional takeover provisions in the Constitution; and to consider other matters.
공시 • Aug 01Archer Materials Limited Further Enhances Biochip gFET Design for Advanced Sensing and Send to Commercial Foundry PartnerArcher Materials Limited has developed a next generation biochip fabrication to better detect and control disease samples on a single graphene field effect transistor ("gFET") design. The gFET design also has functional surfaces and components, for both the sensor and control of the biochip platform. There is also an integration of gFET design components that allow for the real-time fine tuning and control of the electronic properties of the graphene. This has the potential advantage of biosensors that are re-usable, leading to an extended device lifetime. In addition, Archer has improved its biochip system platform testing capabilities to develop a more accurate sensor. The upgraded automated testing platform conducts both control software and readout hardware with improved efficiency. The software is also progressing towards automated data analysis, so end users can extract high quality data. This new more complex gFET design complements the proof-of-concept biosensing gFET announced on 13 July 2023. The earlier design was submitted to a commercial foundry for a Multi-Project Wafer run, with the completed devices expected to be delivered by the end of 2023. The new advanced device designs which are the subject of this announcement have now been submitted to a foundry in the Netherlands for a whole wafer run (the previous 'simpler' design was submitted to a foundry in Germany for a Multi- Project Wafer ("MPW") run). An MPW is where Archer's device design is imprinted on a small area of a wafer with the designs of other companies on the same wafer. The new more complex gFet design will be fabricated all over one, stand-alone four-inch wafer. The new advanced gFET device design and whole wafer run in a commercial foundry is an example of how Archer is now moving towards a streamlined commercialization model that closely aligns to the 'fabless' model (i.e. Archer focuses on designing and developing its chips and outsources the manufacturing to specialized foundries). The new gFET device designs and related processes form the basis of intellectual property that is 100% owned by Archer.
공시 • Jul 14Archer Materials Limited Transfers Biochip Graphene Sensor Technology Design to A Commercial Fab to Verify ScalabilityArcher Materials Limited has completed a proof of concept biosensing graphene transistor for use in its biochip, and submitted the technology design to a commercial foundry to verify scalability. The Archer-designed gFET sensing chips will be produced by a commercial foundry, with the aim of Archer validating its design to ensure appropriate scalability for the manufacturing process. Archer expects completed runs to arrive at the end of 2023. The runs will be evaluated to test which foundry and process are best suited to Archer's technology. Archer's design and process can then be scaled to manufacture complete wafers containing the graphene-based sensors for biochip integration in collaboration with a range of different commercial foundries. Archer has, in parallel, started discussions with potential global foundry partners for initial small production runs of its graphene chip designs to evaluate the reliability of the product. The latest development follows the recent announcement on 10 March 2023 in which the Company gained electronic control of the sensitivity of its incorporated gFET devices so it can better target biomolecules. This followed Archer's early-stage biochip prototype with an integrated system platform for biosensing announced to the market on 16 November 2022, after having developed a 'wettable' gFET announced on 24 October 2022.